Associated Papers
Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Marie V et al.
Journal of Biomolecular Structure & Dynamics, 2022
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O et al.
The Journal of Antimicrobial Chemotherapy, 2020
Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.
Smidt W
Plos One, 2013
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
Koh Y et al.
Journal of Virology, 2011
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA et al.
Antimicrobial Agents and Chemotherapy, 2010
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I et al.
The Journal of Infection, 2007
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Transmission of antiretroviral-drug-resistant HIV-1 variants.
Yerly S et al.
Lancet (london, England), 1999
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.
Molla A et al.
Virology, 1998
Select a paper to view details